Category News

SelectQuote Research Reveals Critical Gaps in Healthcare, Urges Personalized Solutions

SelectQuote Research Reveals Critical Gaps in Medicare Care, Underscoring Need for Personalized Healthcare Solutions OVERLAND PARK, Kan.–(BUSINESS WIRE)–SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and the owner of a rapidly expanding healthcare services platform, today published…

Read MoreSelectQuote Research Reveals Critical Gaps in Healthcare, Urges Personalized Solutions

Merck Reports Phase 3 Results for Once-Daily HIV Regimen Doravirine/Islatravir (DOR/ISL)

Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced new results from its Phase…

Read MoreMerck Reports Phase 3 Results for Once-Daily HIV Regimen Doravirine/Islatravir (DOR/ISL)

Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart (OMS906)

Novo Nordisk Acquires Global Rights to Omeros’ MASP-3 Inhibitor Zaltenibart in $2.1 Billion Agreement Novo Nordisk and Omeros Corporation (Nasdaq: OMER) have entered into a definitive asset purchase and license agreement for zaltenibart (formerly OMS906), a clinical-stage antibody targeting MASP-3…

Read MoreNovo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart (OMS906)